Abstract:Parallel to the increasing prevalence of obesity in the world, the mortality from cardiovascular disease has also increased. Low-grade chronic inflammation in obesity disrupts vascular homeostasis, and the dysregulation of adipocyte-derived endocrine and paracrine effects contributes to endothelial dysfunction. Besides the adipose tissue inflammation, decreased nitric oxide (NO)-bioavailability, insulin resistance (IR), and oxidized low-density lipoproteins (oxLDLs) are the main factors contributing to endothelial dysfunction in obesity and the development of cardiorenal metabolic syndrome. While normal healthy perivascular adipose tissue (PVAT) ensures the dilation of blood vessels, obesity-associated PVAT leads to a change in the profile of the released adipo-cytokines, resulting in a decreased vasorelaxing effect. Higher stiffness parameter β, increased oxidative stress, upregulation of pro-inflammatory cytokines, and nicotinamide adenine dinucleotide phosphate (NADP) oxidase in PVAT turn the macrophages into pro-atherogenic phenotypes by oxLDL-induced adipocyte-derived exosome-macrophage crosstalk and contribute to the endothelial dysfunction. In clinical practice, carotid ultrasound, higher leptin levels correlate with irisin over-secretion by human visceral and subcutaneous adipose tissues, and remnant cholesterol (RC) levels predict atherosclerotic disease in obesity. As a novel therapeutic strategy for cardiovascular protection, liraglutide improves vascular dysfunction by modulating a cyclic adenosine monophosphate (cAMP)-independent protein kinase A (PKA)-AMP-activated protein kinase (AMPK) pathway in PVAT in obese individuals. Because the renin-angiotensin-aldosterone system (RAAS) activity, hyperinsulinemia, and the resultant IR play key roles in the progression of cardiovascular disease in obesity, RAAS-targeted therapies contribute to improving endothelial dysfunction. By contrast, arginase reciprocally inhibits NO formation and promotes oxidative stress. Thus, targeting arginase activity as a key mediator in endothelial dysfunction has therapeutic potential in obesity-related vascular comorbidities. Obesity-related endothelial dysfunction plays a pivotal role in the progression of type 2 diabetes (T2D). The peroxisome proliferator-activated receptor gamma (PPARγ) agonist, rosiglitazone (thiazolidinedione), is a popular drug for treating diabetes; however, it leads to increased cardiovascular risk. Selective sodium-glucose co-transporter-2 (SGLT-2) inhibitor empagliflozin (EMPA) significantly improves endothelial dysfunction and mortality occurring through redox-dependent mechanisms. Although endothelial dysfunction and oxidative stress are alleviated by either metformin or EMPA, currently used drugs to treat obesity-related diabetes neither possess the same anti-inflammatory potential nor simultaneously target endothelial cell dysfunction and obesity equally. While therapeutic interventions with glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide or bariatric surgery reverse regenerative cell exhaustion, support vascular repair mechanisms, and improve cardiometabolic risk in individuals with T2D and obesity, the GLP-1 analog exendin-4 attenuates endothelial endoplasmic reticulum stress.

Relationship Between Insulin and Endothelial Function

The Role of Autophagy of Endothelial Cells in Diabetic Vascular Diseases

Induction of Heme Oxygenase-1 Ameliorates Vascular Dysfunction in Streptozotocin-Induced Type 2 Diabetic Rats.

Insulin Improves the Endothelial Progenitor Cell Mobilization in Diabetic Mice

Insulin Influences the Vasoconstriction Caused by Endothelin-1 in the Hyperglycemic Rat

Insulin Modulates Ischemia-Induced Endothelial Progenitor Cell Mobilization and Neovascularization in Diabetic Mice

Effects of Endothelin Receptor Antagonist on Diabetic Nephropathy

The Effect of Hyperglycemia and Hyperinsulinism on Vascular Complication of Diabetes

A Novel "Endocrine Hormone": The Diverse Role of Extracellular Vesicles in Multiorgan Insulin Resistance

Hypoglycaemia aggravates impaired endothelial-dependent vasodilation in diabetes by suppressing endothelial nitric oxide synthase activity and stimulating inducible nitric oxide synthase expression

Endothelial extracellular vesicles: their possible function and clinical significance in diabetic vascular complications

Endothelial dysfunction in vascular complications of diabetes: a comprehensive review of mechanisms and implications

Endogenous Protective Factors and Potential Therapeutic Agents for Diabetes-Associated Atherosclerosis

Insulin: A connection between pancreatic β cells and the hypothalamus

Insulin ameliorates hypoxia-induced autophagy, endoplasmic reticular stress and apoptosis of myocardial cells: In vitro and ex vivo models

Protective effects of insulin on erectile function in rats with streptozotocin-induced diabetes

Endothelial function and insulin resistance as well as secretion function of insulin in patients with different glucose glycometabolism.

Endothelial Dysfunction in Obesity and Therapeutic Targets

Therapeutic applications of nanomedicine in metabolic diseases by targeting the endothelium

Insulin Therapy is Associated With Increased Myocardial Interstitial Fibrosis and Cardiomyocyte Apoptosis in a Rodent Model of Experimental Diabetes

High-glucose Induced HIF-1α Down-Regulation Impairs the Function of the Endothelial Progenitor Cells Via PI3K/AKT Signaling Pathway